Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Source Summary

WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000 ® Index and the broad-market Russell 3000 ® Index, effective after the close of U.S. equity markets on June 26, 2026.